- Home
- SUPN vs GLPG Comparison
SUPN vs GLPG Comparison
Compare SUPN & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUPN | GLPG |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2012 | 2005 |
Fundamental Metrics
Financial Performance| Metric | SUPN | GLPG |
|---|---|---|
| Price | $45.59 | $31.37 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $63.25 | $31.33 |
| AVG Volume (30 Days) | ★ 1.1M | 149.1K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $681,539,000.00 | $336,643,201.00 |
| Revenue This Year | $8.29 | $1.77 |
| Revenue Next Year | $22.72 | $0.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.54 | ★ 10.31 |
| 52 Week Low | $29.16 | $22.36 |
| 52 Week High | $57.65 | $37.78 |
Technical Indicators
Market Signals| Indicator | SUPN | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 47.45 |
| Support Level | $44.37 | $30.13 |
| Resistance Level | $47.00 | $31.27 |
| Average True Range (ATR) | 1.56 | 0.65 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 55.51 | 36.45 |
Price Performance
Historical ComparisonAbout SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.